FeesSafety
Pluang+

Allarity expands Phase 2 trial of stenoparib to include three ovarian cancer patient groups

Market News
16 Nov 2026, 14:50 WIB
GlobeNewsWire
View Source
Bullish
Allarity expands Phase 2 trial of stenoparib to include three ovarian cancer patient groups

Allarity Therapeutics has expanded its Phase 2 clinical trial of stenoparib, an oral cancer drug, to include three distinct groups of advanced ovarian cancer patients: those with primary platinum-refractory disease, platinum-resistant, and those with clinically evaluable but non-measurable disease. This expansion aims to build on promising early results showing durable clinical benefits and improved survival, potentially accelerating the drug's path to FDA approval. The trial leverages existing clinical sites to efficiently evaluate these groups independently, increasing the chances of broader treatment options for ovarian cancer patients. Positive outcomes could support further development and commercialization of stenoparib across multiple patient populations.

Allarity Therapeutics' expansion of its Phase 2 stenoparib trial is presented here with Pluang's Health-sector market data as of Nov 16, 2026 19:13 WIB. Among 150 priced US Health stocks tradable on Pluang, 67 rose and 61 fell today. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 8.80 with a +3.77% change and a typical hold time of 13 days, Hims and Hers Health Inc (HIMS) at USD 19.01 down -3.65%, and Centene Corp (CNC) at USD 73.80 up +3.55%.

More News

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics reports 38% revenue growth in Q3 2026 and expands IC Drone platform to Greece.

Duke Robotics announced a 38% year-over-year revenue increase for Q3 2026, driven by its IC Drone insulator-cleaning activities. The company expanded its IC Drone platform into Greece through a strategic collaboration with CRONOS, identifying potenti...

Company Fundamentals
Bullish
1 hour ago
Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo and Curio partner to supply recycled nuclear materials for advanced MOX fuel in US reactors

Newcleo plc and Curio Legacy Ventures announced a collaboration to supply recycled nuclear materials for mixed-oxide (MOX) fuel production at Newcleo's planned US fuel manufacturing facility. This partnership combines Curio's NuCycle recycling techno...

Market News
Bullish
1 hour ago
Heineken repurchases over 10 million shares in €1.5 billion buyback program's second tranche

Heineken repurchases over 10 million shares in €1.5 billion buyback program's second tranche

Heineken N.V. has repurchased a total of 10,017,690 shares under the second €750 million tranche of its €1.5 billion share buyback program as of November 13, 2026. The shares were bought both on the exchange and from Heineken Holding N.V., with an av...

Company Fundamentals
Neutral
2 hours ago
eGain launches service to prepare enterprise knowledge for reliable AI use without replacing platforms

eGain launches service to prepare enterprise knowledge for reliable AI use without replacing platforms

eGain Corporation introduced the Trusted Knowledge Service, designed to make existing enterprise knowledge AI-ready and reliable without replacing current platforms like SharePoint and Salesforce. The service includes evaluation, preparation, verific...

Market News
Bullish
2 hours ago
eGain launches Trusted Knowledge Service to prepare enterprise data for reliable AI use without platform changes

eGain launches Trusted Knowledge Service to prepare enterprise data for reliable AI use without platform changes

eGain Corporation has introduced the Trusted Knowledge Service, designed to prepare and certify enterprise knowledge for AI use without replacing existing platforms like SharePoint and Salesforce. The service includes assessment, correction, certific...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App